Millipore Sigma Vibrant Logo
 
Life Science Research
 

Small Molecules for Neurodegeneration Applications

 Request Information
Neurodegenerative diseases are characterized by deterioration of neurons or their myelin sheath, disrupting transmission of sensory information, movement control and more. Because these cells are not easily regenerated, buildup of amyloid plaques can lead to disorders such as Alzheimer’s and Parkinson’s disease, and non-amyloid-related degeneration can cause ALS and MS.

Calbiochem® provides high quality small molecules inhibitors for elucidating the pathogenesis of both amyloid- and non-amyloid-related neurodegeneration, which have been cited in numerous peer-reviewed publications.


Amyloidogenesis Inhibitors

Aβ (β-amyloid peptide) is a major component of neuritic plaques and cerebrovascular amyloid deposits in the brains of patients with Alzheimer’s disease (AD). A long-standing hypothesis has been that Aβ deposits are neurotoxic and are causative factors in the development and progression of AD. Hence, development of inhibitors of Aβ fibrillogenesis has become an important area of research ...

Cholinesterase Inhibitors

A large number of autonomic neurons are cholinergic in nature. Cholinergic terminals contain a large number of small acetylcholine (ACh)-containing, membrane-bound vesicles concentrated near the synaptic end. Following their release from the pre-synaptic end, ACh molecules activate cholinoreceptors on the post-synaptic membrane. Acetylcholinesterase (AChE) is a tetrameric protein that catalyzes the hydrolysis of acetylcholine. AChE inhibitors, which increase the availability of acetylcholine in central synapses, as well as muscarinic agonists, have become the main approach to symptomatic treatment of patients with Alzheimer's disease ...

Monoamine Oxygenase (MAO) Inhibitors

Monoamine Oxygenase (MAO) Inhibitors act by inhibiting the activity of monoamine oxidase, thus preventing the breakdown of monoamine neurotransmitters and thereby increasing their availability.

Secretase Inhibitors

Deposition of Aβ is an early event in the pathogenesis of Alzheimer's disease (AD). The β-amyloid gene, located on chromosome 21, encodes a transmembrane amyloid precursor protein (APP), which gives rise to Aβ. Cleavage of APP by β-secretase and γ-secretases represents the amyloidogenic pathway for processing of APP. The characterization of APP secretases during the past few years has provided significant advancement in therapeutic strategies that may lead to limiting the build-up of Aβ peptide in the brain and eliminate or delay the pathological effects of AD ...

Tau Aggregation Inhibitors

Tau protein aggregation is a hallmark of Alzheimer’s and other degenerative diseases. Aggregation of tau in the neurons is to be toxic to the cells. Tau Aggregation Inhibitors act by hindering this neuronal cell dysfunction.